Xinlitai announced that it recently received the drug registration certificate for Sacubitril Alisartan Calcium Tablets (Xinchaotu) approved and issued by the National Drug Administration. This drug is a new drug developed exclusively by the company and is indicated for primary hypertension. Xinchaotu is the first ARNI drug originally developed in my country and the second approved in the world. The patent protection period of the compound is until 2037. The results of Phase III clinical studies showed that it has significant antihypertensive effect and is clearly dose-dependent. After Xinchaotu is launched on the market, it will form strategic complementarity with Xinlitan and Fulitan in terms of applicable populations and related disease areas, meet more clinical needs, and further enhance the company's comprehensive competitiveness in the field of cardiovascular chronic disease treatment.